Ocera Therapeutics fka OCRX

[longx]

According to SEC filing, the new name for IV OCR-002 is "MNK-6105" and Oral OCR-002 is "MNK-6106"

As part of the acquisition of Ocera in December 2017, the Company provided contingent consideration to the prior shareholders of Ocera in the form of both patient enrollment clinical study milestones for MNK-6105 and MNK-6106 (previously referred to collectively as OCR-002), which represent the IV and Oral formulations, respectively, and sales-based milestones associated with MNK-6105 and MNK-6106. The Company determined the fair value of the contingent consideration based on an option pricing model to be $21.4 million and $22.0 million as of March 30, 2018 and December 29, 2017, respectively.
(Note: a copy of the filing can be found on SA).
https://seekingalpha.com/filing/4012613

They're going to start Phase 2a for MNK-6106 this November and estimated to be completed by 08/30/2019.
https://clinicaltrials.gov/ct2/show/NCT03712280?term=hepatic+encephalopathy+Mallinckrodt&recrs=abf&rank=1
And Phase 3 will be started after that, so I guess we won't receive any payment until late 2019.